Glycotex, Inc. (Glycotex) is a privately held research focused biopharmaceutical company, engaged in discovery and development of innovative drugs to accelerate human wound healing and tissue repair in acute and chronic wounds. The company focuses heavily on its research and development operations for the development of its lead product candidate, GLYC-101. This product is developed under different stages of clinical trials for external acute and chronic wounds including burn wounds, traumatic and surgical wounds, diabetic ulcers and venous ulcers. In addition, the company also develops novel therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications. Glytcotex, Inc. expands patent portfolio in advanced wound healing indications. Glycotex is headquartered at Rockville in Maryland, the US.